Andrew Shinar, MD
Adult Reconstructive Orthopaedic Surgery · Nashville, TNNPI 1619064722
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $147,096 of the $150,563 with a category attached, or 97.7%. Smith+Nephew accounts for 97.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $37,541 and has fallen 64.3% since, to $13,399 in 2025.
Across 25 payments — averaging $6022.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$147K
- Heron Therapeutics, Inc.$3K
- Zimmer Biomet$260
What the payments were for
- Royalty or licence$147,09698%
- Consulting fees$3,0002%
- Food & beverage$4670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 20 | $147,181 |
| Heron Therapeutics, Inc. | 3 | $3,122 |
| Zimmer Biomet | 2 | $260 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REDAPT$138,429
- Legion$8,667
- HTX-011$3,122
- ROSA$130
- Comprehensive Reverse$130
How this compares
$150,563 in reported general payments places this provider in the 85th percentile of 27 adult reconstructive orthopaedic surgery providers in Tennessee.
See all adult reconstructive orthopaedic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 139 | $388 |
| Gabapentin | 11 | $46 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Nashville
- William CarpenterNashville$146K
- Matthew ChristieNashville$47K
- Andrew ThomsonNashville$5K
- Gregory RaabNashville$3K
- Philip KarposNashville$532
- Cory CalendineFranklin$2.5M
- William KurtzBrentwood$774K
- Conrad IvieKnoxville$609K
- Brian PerkinsonFranklin$229K
- Mark FreemanChattanooga$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.